Head Of Marijuana Advocacy Group Americans For Safe Access Stepping Down

Steph Sherer, who founded the medical marijuana advocacy organization Americans for Safe Access in 2002 and ran it ever since as executive director, is stepping down to pursue a new cannabis career in Europe – becoming the latest high-profile MJ reformer to exit their posts.

Sherer plans to split her time between Washington DC and Prague, the Czech Republic capital, where she’ll serve as president of the International Cannabis and Cannabinoids Institute (ICCI), according to a news release.

The ICCI – which Sherer helped found in 2015 – is a collaboration of patient advocates, scientists and a New York-based investment company Dioscorides Global Holdings. Sherer formed Dioscorides in 2014.

The institute intends to work hand-in-hand with governments, private enterprise and universities to further marijuana and hemp reform around the globe.

“For the last 17 years, I have worked to break down societal and governmental barriers for patients who need access to medical cannabis,” Sherer said in the release.

“Now that these barriers are tumbling down, it is important that industry evolves to provide products for these populations that are safe, standardized and targeted and that there is the scientific infrastructure to support these efforts.”

She will remain as president of the board for Americans for Safe Access, though she’ll relinquish her executive director role.

Sherer’s exit from nonprofit marijuana advocacy follows the departures of other longtime reformers such as Ethan Nadelmann from the Drug Policy Alliance and Rob Kampia from the Marijuana Policy Project.

Original Article Source: https://mjbizdaily.com/head-cannabis-advocacy-group-americans-for-safe-access-stepping-down/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

A Dozen US Governors Ask Congressional Leaders To Back Federal Marijuana Reform

A bipartisan coalition of 12 governors from states that have legalized medical or recreational cannabis sent a letter to congressional leaders, asking for their support in getting a major marijuana reform bill through the U.S. House and Senate. The governors of California, Colorado, Maryland, Massachusetts, Nevada, New York, North Dakota, Oregon, Pennsylvania, Utah, Vermont and Washington state are backing the STATES Act – which would codify in federal law that marijuana regulations are to be left to the states instead of the federal government – while also seeking protections on banking and tax issues for the MJ industry. “The STATES Act is not about whether marijuana should be legal or illegal; it is about respecting the authority of states to act, lead and respond to the evolving needs and attitudes of their citizens,” the governors wrote. The letter also expressed support for the SAFE Banking Act , which was approved in March by a House committee. Tha...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Norma Pence

Search This Blog